CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.
FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label
November 23, 2024